Palvella Therapeutics (PVLA) Net Income towards Common Stockholders (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$15.8 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 92.63% year-over-year to -$15.8 million in Q1 2026; TTM through Mar 2026 was -$49.4 million, a 115.65% decrease from a year earlier, with the FY2025 full-year figure at -$41.8 million, down 139.64% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$15.8 million, down from -$12.8 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for PVLA reached as high as $15.0 million in Q4 2023 and fell as low as -$16.0 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged -$7.8 million across 5 years, with a median of -$9.5 million in 2025.
• Across the five-year window, Net Income towards Common Stockholders jumped 221.65% in 2023 and slumped 379.33% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$12.3 million in 2022, then soared by 221.65% to $15.0 million in 2023, then tumbled by 122.48% to -$3.4 million in 2024, then tumbled by 279.28% to -$12.8 million in 2025, then decreased by 23.39% to -$15.8 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$15.8 million in Q1 2026, -$12.8 million in Q4 2025, and -$11.3 million in Q3 2025.